Skip to main content
Log in

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Purpose

Recent studies have been conducted on the relationship between fluorodeoxyglucose (FDG) uptake in F-18 FDG PET/CT and prognosis in patients with pancreatic cancer, but these studies have been carried out in small numbers of patients. The aim of this retrospective study was to determine in a large number of patients whether glucose metabolism as assessed by F-18 FDG PET/CT provides prognostic information independent of established prognostic factors in patients with pancreatic cancer.

Methods

We reviewed retrospectively the medical records of 165 patients (men 105, women 60, mean age 67 ± 10 years) with a diagnosis of pancreatic cancer that had undergone F-18 FDG PET/CT as part of a pretreatment workup from January 2004 to December 2009. Subsequently, all patients underwent surgery, cyberknife, radiotherapy, and/or chemotherapy. For the analysis, patients were classified by age, demographic data, maximum standardized uptake value (SUVmax), size, location, serum level of CA19-9, type of treatment, and AJCC stage. The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier with log-Rank test and Cox’s proportional-hazard regression methods.

Results

Median survival for all 165 study subjects was 290 days and median SUV by PET/CT was 5.8 (range: 0–25.1). Patients were allocated to high (> 4.1) and low (≤4.1) SUV groups, and median survivals of these patients were 229 days and 610 days, respectively, which were significantly different (p < 0.0001). Furthermore, SUVmax was found to be significantly related to survival in each stage, i.e., there were 1267 days in stage I, 440 days in stage II, 299 days in stage III, and 143 days in stage IV (p < 0.0001). The median survival was also found to be significantly related to tumor size (p = 0.001), site (p = 0.0298), serum level of CA19-9 (p = 0.0017), distant metastasis (p < 0.0001), and type of treatment (p < 0.0001). Multivariate analysis study revealed that the patients with a low SUV (p = 0.0298), a lower serum level of CA19-9 (p = 0.0071), a lower stage (p = 0.0017), and no distant metastasis (p < 0.0001) had longer survivals. In addition, SUVmax values were found to have a similar hazard ratio of distant metastasis; it was well known predictor. Furthermore, SUVmax values showed a higher hazard ratio than that of other clinicopathologic predictors.

Conclusion

The present study shows that SUVmax on F-18 FDG PET/CT can provide a prognostic information in patients with pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. In: SEER Cancer Statistics Review 1975-2008. National Cancer Institute. Bethesda, http://seer.cancer.gov/csr/1975_2008/ based on November 2010 SEER data submission, posted to the SEER web site, 2011.

  2. In: Cancer Statistics in Korea, National Cancer information center, http://www.Cancer.go.kr/ncic/cicis_f/01/012/index.html, 2012

  3. Morganti AG, Brizi MG, Macchia G, Sallustio G, Costamagna G, Alfieri S, et al. The prognostic effect of clinical staging in pancreatic adenocarcinoma. Ann Surg Oncol. 2005;12:145–51.

    Article  PubMed  Google Scholar 

  4. Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobillary Pancreat Surg. 2006;13(5):435–41.

    Article  Google Scholar 

  5. Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77(5):1420–5.

    Article  PubMed  Google Scholar 

  6. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin N Am. 2001;39:883–917.

    Article  PubMed  CAS  Google Scholar 

  7. Hustinx R, Benard F, Alavi A. Whole-body imaging in the management of patients with cancer. Sem Nucl Med. 2002;32:35–46.

    Article  Google Scholar 

  8. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18 F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39–45.

    PubMed  Google Scholar 

  9. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–11.

    PubMed  CAS  Google Scholar 

  10. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET. Cancer Imaging. 2008;8:70–80.

    Article  PubMed  Google Scholar 

  11. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakural Y, Sawada T, et al. 18 F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997;79:695–9.

    Article  PubMed  CAS  Google Scholar 

  12. Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18 F-fluoro-deoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol. 2001;19:53–8.

    PubMed  CAS  Google Scholar 

  13. Zimmy M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, Schumpelick V, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol. 2000;35:883–8.

    Article  Google Scholar 

  14. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7:953–9.

    Article  PubMed  Google Scholar 

  15. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction and of outcome. Ann Surg. 2011;254(2):311–9.

    Article  PubMed  Google Scholar 

  16. Fujino Y, Suzuki Y, Allki T, Tanioka Y, Kuroda Y. Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. Hepatogastroenterology. 2003;50:250–3.

    PubMed  Google Scholar 

  17. Benassai G, Mastrorilli M, Mosella F, Mosella G. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res. 1999;18:23–8.

    PubMed  CAS  Google Scholar 

  18. Wilkowski R, Wolf M, Heinemann V. Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res. 2008;177:79–93.

    Article  PubMed  CAS  Google Scholar 

  19. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP. 2006;7(4):349–60.

    PubMed  Google Scholar 

  20. Oya N. Chemoradiotherapy for pancreatic cancer: current status and perspectives. Int J Clin Oncol. 2004;9:451–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

We declare that we have no conflict of interest

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sang Moo Lim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hwang, J.P., Lim, I., Chang, K.J. et al. Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer. Nucl Med Mol Imaging 46, 207–214 (2012). https://doi.org/10.1007/s13139-012-0151-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-012-0151-y

Keywords

Navigation